Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711698 | 0.89 | ALB (0.52) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6708744 | 0.84 | ALB (0.65) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6710405 | 0.84 | ALB (0.46) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6710136 | 0.83 | ALB (0.62) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6710108 | 0.82 | ALB (0.56) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6710368 | 0.81 | MAPT (0.53) | ALBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL6708577 | 0.81 | ALB (0.54) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6710088 | 0.81 | ALB (0.49) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6709196 | 0.79 | THRB (0.46) | ALBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6346566 | 0.79 | ALB (1.00) | ALBKMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | ALB 1298/4885KMT2A 3181/4885MEN1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.